KENACORT

Kenacort Adverse Events Reported to the FDA Over Time

How are Kenacort adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Kenacort, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Kenacort is flagged as the suspect drug causing the adverse event.

Most Common Kenacort Adverse Events Reported to the FDA

What are the most common Kenacort adverse events reported to the FDA?

Anaphylactic Shock	14 (2.58%)
Endophthalmitis	13 (2.4%)
Intraocular Pressure Increased	9 (1.66%)
Retinal Artery Occlusion	9 (1.66%)
Drug Interaction	8 (1.48%)
Scleral Thinning	8 (1.48%)
Anaphylactic Reaction	7 (1.29%)
Cytomegalovirus Chorioretinitis	7 (1.29%)
Injection Site Atrophy	7 (1.29%)
Malaise	7 (1.29%)
Blindness Unilateral	6 (1.11%)
	Show More
Cardiac Arrest	6 (1.11%)
Injection Site Pain	6 (1.11%)
Oesophageal Perforation	6 (1.11%)
Retinal Detachment	6 (1.11%)
Synovitis	6 (1.11%)
Tendon Rupture	6 (1.11%)
Adverse Event	5 (.92%)
Arthritis Bacterial	5 (.92%)
Cataract	5 (.92%)
Cellulitis	5 (.92%)
Chorioretinopathy	5 (.92%)
Depressed Mood	5 (.92%)
Drug Ineffective	5 (.92%)
Glaucoma	5 (.92%)
Haemarthrosis	5 (.92%)
Myocardial Infarction	5 (.92%)
Osteoporosis	5 (.92%)
Pregnancy	5 (.92%)
Transmission Of An Infectious Agent...	5 (.92%)
Adrenal Insufficiency	4 (.74%)
Anaphylactoid Reaction	4 (.74%)
Atrophy	4 (.74%)
Conjunctival Haemorrhage	4 (.74%)
Muscle Atrophy	4 (.74%)
Pain	4 (.74%)
Placental Chorioangioma	4 (.74%)
Retinal Pigment Epitheliopathy	4 (.74%)
Retinal Tear	4 (.74%)
Vision Blurred	4 (.74%)
Anxiety Disorder	3 (.55%)
Arthritis	3 (.55%)
Blood Cortisol Decreased	3 (.55%)
Blood Pressure Decreased	3 (.55%)
Cellulitis Orbital	3 (.55%)
Chest Pain	3 (.55%)
Convulsion	3 (.55%)
Crystal Arthropathy	3 (.55%)
Cushingoid	3 (.55%)
Diabetes Mellitus	3 (.55%)
Erythema	3 (.55%)
Extradural Abscess	3 (.55%)
Eye Abscess	3 (.55%)
Fatigue	3 (.55%)
Gastrointestinal Perforation	3 (.55%)
Herpes Zoster	3 (.55%)
Humerus Fracture	3 (.55%)
Hyperglycaemia	3 (.55%)
Hypertension	3 (.55%)
Joint Instability	3 (.55%)
Lichen Planus	3 (.55%)
Lichen Striatus	3 (.55%)
Muscular Weakness	3 (.55%)
Necrotising Scleritis	3 (.55%)
Paraesthesia	3 (.55%)
Psoas Abscess	3 (.55%)
Pyelonephritis Acute	3 (.55%)
Respiratory Arrest	3 (.55%)
Sensation Of Heaviness	3 (.55%)
Skin Atrophy	3 (.55%)
Throat Tightness	3 (.55%)
Tinnitus	3 (.55%)
Urticaria	3 (.55%)
Uterine Disorder	3 (.55%)
Visual Acuity Reduced	3 (.55%)
Accidental Overdose	2 (.37%)
Altered State Of Consciousness	2 (.37%)
Arthralgia	2 (.37%)
Asthma	2 (.37%)
Back Pain	2 (.37%)
Cardio-respiratory Arrest	2 (.37%)
Cerebral Infarction	2 (.37%)
Cerebrovascular Accident	2 (.37%)
Chorioretinal Disorder	2 (.37%)
Cytolytic Hepatitis	2 (.37%)
Death	2 (.37%)
Depression	2 (.37%)
Dermatitis	2 (.37%)
Disseminated Intravascular Coagulat...	2 (.37%)
Eczema	2 (.37%)
Eye Excision	2 (.37%)
Eye Infection Fungal	2 (.37%)
Eye Inflammation	2 (.37%)
Eyelid Ptosis	2 (.37%)
Faecal Incontinence	2 (.37%)
Flushing	2 (.37%)
Haemorrhage	2 (.37%)
Haemorrhagic Anaemia	2 (.37%)
Hypoaesthesia	2 (.37%)
Injection Site Abscess	2 (.37%)
Injection Site Necrosis	2 (.37%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Kenacort, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Kenacort is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Kenacort

What are the most common Kenacort adverse events reported to the FDA?

Ocular Structural Change, Deposit A...	32 (5.9%)
Infections - Pathogen Unspecified	30 (5.54%)
Allergic Conditions	26 (4.8%)
Epidermal And Dermal Conditions	21 (3.87%)
Administration Site Reactions	19 (3.51%)
Joint	19 (3.51%)
Therapeutic And Nontherapeutic Effe...	18 (3.32%)
Retina, Choroid And Vitreous Hemorr...	17 (3.14%)
Bacterial Infectious	16 (2.95%)
Ocular Infections, Irritations And ...	15 (2.77%)
Vision	14 (2.58%)
	Show More
Gastrointestinal Ulceration And Per...	12 (2.21%)
Neurological	12 (2.21%)
Injuries	11 (2.03%)
Cardiac Arrhythmias	10 (1.85%)
Neurological, Special Senses And Ps...	10 (1.85%)
Viral Infectious	10 (1.85%)
Muscle	9 (1.66%)
Pregnancy, Labour, Delivery And Pos...	9 (1.66%)
Bone Disorders	8 (1.48%)
Adrenal Gland	7 (1.29%)
Depressed Mood Disorders	7 (1.29%)
Anxiety Disorders	6 (1.11%)
Bone And Joint Injuries	6 (1.11%)
Coronary Artery	6 (1.11%)
Glaucoma And Ocular Hypertension	6 (1.11%)
Glucose Metabolism Disorders	6 (1.11%)
Musculoskeletal And Connective Tiss...	6 (1.11%)
Ocular Hemorrhages And Vascular	6 (1.11%)
Respiratory	6 (1.11%)
Synovial And Bursal	6 (1.11%)
Tissue	6 (1.11%)
Ancillary Infectious Topics	5 (.92%)
Anterior Eye Structural Change, Dep...	5 (.92%)
Anemias Nonhemolytic And Marrow Dep...	4 (.74%)
Central Nervous System Vascular	4 (.74%)
Decreased And Nonspecific Blood Pre...	4 (.74%)
Inner Ear And Viiith Cranial Nerve	4 (.74%)
Medication Errors	4 (.74%)
Reproductive Neoplasms Female Benig...	4 (.74%)
Angiedema And Urticaria	3 (.55%)
Cardiac And Vascular Investigations	3 (.55%)
Cornification And Dystrophic Skin	3 (.55%)
Endocrine Investigations	3 (.55%)
Fungal Infectious	3 (.55%)
Gastrointestinal Signs	3 (.55%)
Hepatic And Hepatobiliary	3 (.55%)
Menstrual Cycle And Uterine Bleedin...	3 (.55%)
Movement Disorders	3 (.55%)
Seizures	3 (.55%)
Skin And Subcutaneous Tissue	3 (.55%)
Sleep Disorders	3 (.55%)
Uterine, Pelvic And Broad Ligament	3 (.55%)
Vascular Hypertensive	3 (.55%)
Bronchial Disorders	2 (.37%)
Changes In Physical Activity	2 (.37%)
Coagulopathies And Bleeding Diathes...	2 (.37%)
Eye	2 (.37%)
Eye Therapeutic Procedures	2 (.37%)
Fatal Outcomes	2 (.37%)
Ocular Neuromuscular	2 (.37%)
Psychiatric	2 (.37%)
Skin Appendage Conditions	2 (.37%)
Skin Vascular Abnormalities	2 (.37%)
Tongue Conditions	2 (.37%)
Vascular	2 (.37%)
Vascular Hemorrhagic	2 (.37%)
White Blood Cell	2 (.37%)
Cardiac Disorder Signs	1 (.18%)
Chemical Injury And Poisoning	1 (.18%)
Deliria	1 (.18%)
Embolism And Thrombosis	1 (.18%)
Gastrointestinal Conditions	1 (.18%)
Gastrointestinal Hemorrhages	1 (.18%)
Headaches	1 (.18%)
Increased Intracranial Pressure And...	1 (.18%)
Miscellaneous And Site Unspecified ...	1 (.18%)
Mood Disorders	1 (.18%)
Neuromuscular	1 (.18%)
Obstetric And Gynecological Therape...	1 (.18%)
Ocular Sensory Symptoms	1 (.18%)
Peritoneal And Retroperitoneal Cond...	1 (.18%)
Personality Disorders	1 (.18%)
Physical Examination Topics	1 (.18%)
Pigmentation	1 (.18%)
Procedural And Device Related Injur...	1 (.18%)
Schizophrenia And Other Psychotic	1 (.18%)
Suicidal And Self-injurious Behavio...	1 (.18%)
Thoracic Disorders	1 (.18%)
Thyroid Gland	1 (.18%)
Vulvovaginal Disorders	1 (.18%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Kenacort, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Kenacort is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.